Lauren Dembeck, PhD, is a freelance science & medical writer. She specializes in medicine and healthcare, with a focus on various medical specialties including hematology, immunology, oncology, and mental health care. Her work has been featured in publications such as Oncology Nurse Advisor, Infectious Disease Advisor, and The Cardiology Advisor, among others.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Lauren Dembeck's articles predominantly cite data related to medical research, hematology, cancer treatment, and blood disorders. She appears to focus on scientific themes within the healthcare and pharmaceutical sector. Given her reliance on data-backed information, she may be interested in receiving pitches from researchers or professionals with access to new and significant datasets or those who can provide expert analysis of existing ones.
Lauren appears to have a broad international scope rather than a specific geographic focus. Her coverage seems centered around developments in medical research and treatments globally without being limited to any particular region.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Hospital-acquired RSV drives a disproportionate share of pediatric deaths—far deadlier than community-acquired infections.
By: Lauren Dembeck
Behavioral therapies, especially those classed as brain-gut behavior therapy, significantly improve global symptoms in adults with irritable bowel syndrome (IBS), according to a large network meta-analysis published in The Lancet Gastroenterology & Hepatology.
By: Lauren Dembeck
Recombinant von Willebrand factor (rVWF) provides effective and reliable perioperative hemostatic control for adults with von Willebrand disease (VWD), according to new research published in the European Journal of Haematology.
By: Lauren Dembeck
A novel patient-reported outcome tool designed to capture home-managed sickle cell pain crises (SCPC) demonstrated strong content validity in adolescents and adults with sickle cell disease (SCD), according to research published in Advances in Therapy. The newly developed eDiary captures the frequency, severity, and functional impact of pain crises, addressing a longstanding gap in standardized tools for assessing patient experiences outside clinical settings.
By: Lauren Dembeck
Infectious complications, including endemic opportunistic infections, remain a significant risk following CD19-directed chimeric antigen receptor (CAR) T-cell therapy, according to a real-world cohort study published in Blood Global Hematology. The findings underscore the need for region-specific post-CAR T surveillance strategies.
By: Lauren Dembeck
A novel patient-reported outcome tool designed to capture home-managed sickle cell pain crises (SCPC) demonstrated strong content validity in adolescents and adults with sickle cell disease (SCD), according to research published in Advances in Therapy. The newly developed eDiary captures the frequency, severity, and functional impact of pain crises, addressing a longstanding gap in standardized tools for assessing patient experiences outside clinical settings.
By: Lauren Dembeck
A shortened, outpatient blinatumomab regimen incorporating vial-sharing strategies and resulting in substantial cost savings appears to be safe and feasible in children with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (ALL) in resource-limited settings, according to a retrospective study published in JCO Global Oncology.
By: Lauren Dembeck
Late acute and chronic graft vs host disease (GVHD) remain frequent complications and continue to drive long-term mortality following allogeneic hematopoietic cell transplantation (HCT), according to a 10-year follow-up study from the Chronic GVHD Consortium published in
By: Lauren Dembeck
Gasoyan H, Raza S, Rothberg MB, et al. Overall survival of Black patients with newly diagnosed multiple myeloma in the era of triplet and quadruplet therapies . ASCO 2026.
By: Lauren Dembeck
Golidocitinib maintenance therapy yields durable remissions and manageable toxicity among patients with peripheral T-cell lymphoma (PTCL) who respond to first-line therapy, according to a phase 2 multicenter study published in Blood Cancer Journal.
